RLM.L Regulatory News (RLM)

21 Feb 2008 07:01

PuriCore Plc21 February 2008 PuriCore plc Notification of Directors' and PDMRs' Option Holdings MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 21 February 2008 - PuriCore (LSE:PURI), the life sciences company focused on the control of infectious pathogenswith its novel, safe antimicrobial technology, announces that on 20 February2008 the following options over Ordinary Shares in the Company were granted tothe following Directors and PDMRs under the terms of the PuriCore plc ExecutiveOmnibus Incentive Plan. Executive Director Position Options Granted Total Options HeldGregory Bosch Chief Executive Officer 1,328,000 5,356,100Keith A. Goldan Chief Financial Officer 769,000 2,219,000 The options to the Executive Directors are to vest on the third anniversary ofthe date of grant subject to the achievement of performance conditions,exercisable from the date of vesting until the tenth anniversary of the date ofgrant, at an exercise price of 30.5 pence per share. Director Position Options Granted Total Options HeldChristopher Wightman Non-Executive Chairman 140,000 4,640,000Bishop Allen Non-Executive Director 41,000 491,000Timothy Anderson Non-Executive Director 41,000 141,000Joseph William Birkett Senior Independent Director 50,000 320,000Michael Sapountzoglou Non-Executive Director 50,000 320,000Alan Suggett, PhD Non-Executive Director 41,000 141,000James Walsh, PhD Non-Executive Director 41,000 141,000 The options to the Non-Executive Directors are to vest in amounts of one-thirdof the total grant per year over three years, exercisable from the date ofvesting until the tenth anniversary of the date of grant, at an exercise priceof 30.5 pence per share. PDMR Position Options Granted Total Options HeldDaniel Bee Managing Director, PuriCore 175,000 325,000 InternationalDavid Correale Vice President, Marketing 230,000 530,000 and Business DevelopmentThomas Daniel Senior Vice President and 280,000 880,000 General Manager, Sterilox Food SafetyAndrea Drucker Senior Vice President 280,000 580,000 General Counsel, and Company SecretaryRaymond Mannion Vice President, Operations 230,000 580,000 The options to the PDMRs are to vest in amounts of one-third of the total grantper year over three years, exercisable from the date of vesting until the tenthanniversary of the date of grant at an exercise price of 30.5 pence per share. The current issued ordinary share capital of the Company is 152,888,792. Enquiries: Ben Brewerton Greg Bosch, CEOSusan Quigley Keith A. Goldan, CFOFinancial Dynamics PuriCore+44 (0) 20 7831 3113 +1 484 321 2700 About PuriCore PuriCore plc (LSE: PURI) is a life sciences company focused on developing andcommercialising proprietary products that safely, effectively, and naturallykill contagious pathogens. PuriCore's technology provides a solution to a broadrange of markets that depend upon controlling contamination, including foodsafety in retail and foodservice, medical device disinfection, wound therapy,and hospitality. The Company's proprietary technology mimics the human body'sproduction of the natural antimicrobial hypochlorous acid, which is highlyeffective in killing bacteria, viruses, and fungal spores. Deployinghypochlorous acid solutions as soaks, sprays, mists, and in other forms,PuriCore's technology is designed to limit the spread of infectious disease,including major public health threats of M. tuberculosis, MRSA, E.coli,Norovirus, Avian Influenza, HIV, Polio Virus, Helicobater pylori, andLegionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices inStafford, UK. To receive additional information on PuriCore, please visit our website atwww.puricore.com, which does not form part of this press release. Certain statements made in this announcement are forward-looking statements.These forward-looking statements are not historical facts but rather are basedon the Company's current expectations, estimates, and projections about itsindustry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,''intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressionsare intended to identify forward-looking statements. These statements are notguarantees of future performance and are subject to known and unknown risks,uncertainties, and other factors, some of which are beyond the Company'scontrol, are difficult to predict, and could cause actual results to differmaterially from those expressed or forecasted in the forward-looking statements.The Company cautions shareholders and prospective shareholders not to placeundue reliance on these forward-looking statements, which reflect the view ofthe Company only as of the date of this announcement. The forward-lookingstatements made in this announcement relate only to events as of the date onwhich the statements are made. The Company will not undertake any obligation torelease publicly any revisions or updates to these forward-looking statements toreflect events, circumstances, or unanticipated events occurring after the dateof this announcement except as required by law or by any appropriate regulatoryauthority. This information is provided by RNS The company news service from the London Stock Exchange